<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00452114</url>
  </required_header>
  <id_info>
    <org_study_id>H-11138</org_study_id>
    <nct_id>NCT00452114</nct_id>
  </id_info>
  <brief_title>In-exsufflator Cough Assist Device in Patients With Symptomatic Bronchiectasis</brief_title>
  <official_title>A Randomized, Controlled Study Evaluating the Effectiveness of the Inexsufflator Cough Assist Device in Patients With Symptomatic Bronchiectasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Massachusetts, Worcester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, controlled trial examining the effectiveness of the mechanical
      cough-assist device (in-exsufflator) in promoting the clearance of retained airway secretions
      in patients with symptomatic bronchiectasis. We hypothesize that this enhanced clearance of
      airway secretions will lead to a decline in the number of acute exacerbations of
      bronchiectasis experienced by these patients during the study period, improve health-related
      quality of life, decrease overall health-care costs and improve pulmonary function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bronchiectasis is characterized by airway dilatation with the potential to cause devastating
      illness, including repeated respiratory infections requiring antibiotics, disabling
      productive, mucopurulent cough, shortness of breath and occasional hemoptysis. The damaged
      and dilated airways lead to persisting bacterial infection of the bronchi and bronchioles,
      causing inflammation and retained secretions, which in turn may further damage the airways.
      Patients typically suffer from frequent, severe and refractory episodes of bacterial
      bronchitis, often requiring hospitalization and prolonged courses of antibiotics. The
      pathophysiology of bronchiectasis involves the retention of viscid, tenacious inflammatory
      secretions and microbes leading to a &quot;vicious cycle&quot; of airway obstruction, destruction and
      recurrent infection with further compromise of the mucociliary clearance host defense
      apparatus. It has been widely proposed and recommended that methods of enhancing clearance of
      airway secretions should be an integral component of the care of patients with
      bronchiectasis. Despite these recommendations and a sound pathophysiologic plausibility given
      the central role retention of secretions plays in the disease, the effectiveness of
      interventions targeted toward enhancing bronchopulmonary hygiene has not been systematically
      studied. It is also not known whether the ability to generate an adequate cough would predict
      which patient will benefit from these interventions.

      The mechanical in-exsufflator device assists patients in clearing retained secretions by
      augmenting the expiratory flow and force of the patient's cough with the addition of a cycle
      of positive and negative inspiratory pressure. An effective cough mechanism is actually an
      important and beneficial host defense which aids in mucus clearance along with the
      mucociliary apparatus. We hypothesize that daily, regular use of the in-exsufflator device
      will lead to a reduction in acute bronchiectasis exacerbations- a clinically meaningful
      endpoint- with other possible beneficial outcomes including improved pulmonary function,
      improved health-related quality of life and decreased health care costs.

      Despite the lack of rigorous, well-designed studies supporting the role and most effective
      mode of bronchial hygiene physiotherapy in patients with bronchiectasis, many Pulmonologists
      recommend the flutter valve device as the generally accepted &quot;standard of care&quot; at this time
      due to its relative non-invasiveness, ease of use and high level of patient acceptability.
      The flutter valve is a simple, hand-held, pipe-like device which helps loosen secretions by
      providing an expiratory low-pressure vibratory pulse to the patient's airway when used. This
      study will provide a comparison of the clinical efficacy of these mechanical chest
      physiotherapy devices in the setting of bronchiectasis.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    interim analysis indicates statistical futility for primary outcomes
  </why_stopped>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Suppurative Exacerbations Per Patient Per Year</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Hospitalizations and Urgent/Unscheduled Outpatient Visits</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (St. George's Respiratory Questionnaire, Cough-Specific Quality of Life Questionnaire)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Function: FEV1</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Expiratory Cough Flow</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Bronchiectasis</condition>
  <arm_group>
    <arm_group_label>In-Exsufflator Cough Assist Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In-Exsufflator Cough Assist Device augments the expiratory flow and force of the patient's cough with the addition of a cycle of positive and negative inspiratory pressure when used daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>flutter valve device</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>flutter valve device delivers expiratory low-pressure vibratory pulse to the patient's airway when used daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>In-Exsufflator Cough Assist Device</intervention_name>
    <arm_group_label>In-Exsufflator Cough Assist Device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active Comparator: Flutter Valve Device</intervention_name>
    <description>Active Comparator</description>
    <arm_group_label>flutter valve device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chest CT scan confirmation of bronchiectasis

          -  At least two exacerbations in the preceding 12 months requiring antibiotics

        Exclusion Criteria:

          -  Cystic fibrosis

          -  Bullous emphysema

          -  History of spontaneous pneumothorax

          -  History of massive hemoptysis: greater than 200 cc in a 24 hour period

          -  Lung resection surgery in the past 6 months

          -  Use of the mechanical cough in-exsufflator in the prior 3 months

          -  Inability to speak and read English

          -  Inability to demonstrate proper use of the cough-assist or flutter device

          -  Unable to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen J Krinzman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Massachusetts, Worcester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UMass Memorial Medical Center, Universty Campus</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2007</study_first_submitted>
  <study_first_submitted_qc>March 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2007</study_first_posted>
  <results_first_submitted>January 30, 2013</results_first_submitted>
  <results_first_submitted_qc>January 30, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 6, 2013</results_first_posted>
  <last_update_submitted>March 15, 2018</last_update_submitted>
  <last_update_submitted_qc>March 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bronchiectasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>In-Exsufflator Cough Assist Device</title>
          <description>In-Exsufflator Cough Assist Device augments the expiratory flow and force of the patient's cough with the addition of a cycle of positive and negative inspiratory pressure when used daily</description>
        </group>
        <group group_id="P2">
          <title>Flutter Valve Device</title>
          <description>flutter valve device delivers expiratory low-pressure vibratory pulse to the patient's airway when used daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>In-Exsufflator Cough Assist Device</title>
          <description>In-Exsufflator Cough Assist Device augments the expiratory flow and force of the patient's cough with the addition of a cycle of positive and negative inspiratory pressure when used daily</description>
        </group>
        <group group_id="B2">
          <title>Flutter Valve Device</title>
          <description>flutter valve device delivers expiratory low-pressure vibratory pulse to the patient's airway when used daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Suppurative Exacerbations Per Patient Per Year</title>
        <time_frame>12 months</time_frame>
        <population>interim analysis indicates statistical futility for primary outcomes</population>
        <group_list>
          <group group_id="O1">
            <title>Participants in the Intervention Group (Cough In-exsufflator)</title>
          </group>
          <group group_id="O2">
            <title>Particpants in the Control Group (Flutter Device)</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Suppurative Exacerbations Per Patient Per Year</title>
          <population>interim analysis indicates statistical futility for primary outcomes</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Hospitalizations and Urgent/Unscheduled Outpatient Visits</title>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life (St. George's Respiratory Questionnaire, Cough-Specific Quality of Life Questionnaire)</title>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulmonary Function: FEV1</title>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Expiratory Cough Flow</title>
        <time_frame>12 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>In-Exsufflator Cough Assist Device</title>
          <description>In-Exsufflator Cough Assist Device augments the expiratory flow and force of the patient's cough with the addition of a cycle of positive and negative inspiratory pressure when used daily</description>
        </group>
        <group group_id="E2">
          <title>Flutter Valve Device</title>
          <description>flutter valve device delivers expiratory low-pressure vibratory pulse to the patient's airway when used daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stephen Krinzman, Principal Investigator</name_or_title>
      <organization>University of Massachusetts Medical School</organization>
      <phone>508-856-1975</phone>
      <email>stephen.krinzman@umassmed.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

